Company Focus

Capnosway’s wearable capnographs works for all patients and situations. However, sleep apnea diagnostics is a field were current capnography technologies fall short and the main benefits from Capnosway will be filling the unmet need.

Sleep apnea is an increasingly prevalent disease, that can have severe consequences when remaining untreated. Polysomnography (PSG) is the gold standard in sleep apnea diagnostics, but current PSG solutions only ensure accurate diagnosis of sleep apnea in the hospital setting.

Luciana Rabello de Oliveira, clinical director at ResMed says:

“Some benefits of homesleep tests are greater accessibility to testing for people who are unable or unwilling to stay at an overnight clinic, high clinical accuracy of some HSATs [homesleep apnea tests] for diagnosing obstructive sleep apnea, and cloud connectivity with certain HSATs that enable patients’ doctors to quickly see their results, reducing the time it takes to get people with sleep apnea the therapy solution they need.”

Homecare sleep monitoring solutions cannot easily be equipped with capnography due to parameters such as wearability, noise and cost, and hence fail to diagnose the disorder accurately.

Capnosway’s technologies will meet these needs as well as the following three main points from the American Academy of Sleep Medicine (AAST) ETCO2 guidelines:

“During PSG, CO2 monitoring is recommended for the following patient populations where hypoventilation can have adverse effects on development, comorbid disease and mortality: pediatric; neuromuscular disease; respiratory failure; hypoventilation.”

“The main source of difficulty in maintaining a reliable ETCO2 Signal is occlusion of the sampling line.”

“It is recommended that sleep centers using EtCO2 utilize a split cannula for simultaneous monitoring of CO2 and Pflow rather than attempting to place two separate Pflow and EtCO2 cannulas on a patient.”

The unmet need of capnography is since 2015 included in the fee schedule for pediatric polysomnography (PSG).